David Vanderlugt, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3988 W State Road 10, Wheatfield, IN 46392 Phone: 219-987-3581 Fax: 219-987-7137 |
News Archive
ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.
Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the generic version of Novartis' Exforge. Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for amlodipine and valsartan and was granted 180 days of marketing exclusivity.
A higher number of previous mood episodes and living in a mixed urban/rural area are associated with an increased risk for relapse in patients with bipolar disorder, Spanish researchers report.
A biomedical engineer researcher at Indiana University-Purdue University Indianapolis has received a $419,000 National Institutes of Health grant to uncover why mechanical loading of bones increases their resistance to fractures.
› Verified 5 days ago